MEDXF News and Press, Medexus Pharmaceuticals Inc From 02/07/24

Fiscal Q3 2024 revenue of $25.2 million, Operating income of $1.6 million, and Adjusted EBITDA* of $3.2 million Management to host conference call at 8:00 AM Eastern time on Thursday, February 8, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 7, 2024) - Medexus Pharm...

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 8, 2024 to discuss Medexus's results for its third fiscal quarter ended December 31, 20...

Topical terbinafine has been widely used in other markets to treat fungal nail infections If and when approved, the product will enter the topical fungicides market that is estimated to be C$88 million on an annual basis* Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 8, 2...

2023-11-11 12:39:13 ET Medexus Pharmaceuticals, Inc. (MEDXF) Q2 2024 Earnings Conference Call November 07, 2023 08:00 AM ET Company Participants Magda Gardner - IR Representative, Adelaide Capital Kenneth d'Entremont - Chief Executive Officer and Director Marcel ...

Fiscal Q2 2024 revenue reflects a 9.4% increase over fiscal Q2 2023, demonstrating strong revenue growth and continued overall performance Management to host conference call at 8:00 AM Eastern time on Thursday, November 9, 2023 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - Novemb...

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 1, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 9, 2023 to discuss Medexus's results for its second fiscal quarter ended September 30, ...

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 17, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that, in connection with its recently completed bought-deal public offering ( Offering ) of units ( Units ), Medexus has issued an additional 508,...

2023-10-16 10:37:47 ET More on Medexus Pharmaceuticals Medexus Pharmaceuticals Inc (MEDXF) Q1 2024 Earnings Call Transcript Historical earnings data for Medexus Pharmaceuticals Inc. Financial information for Medexus Pharmaceuticals Inc. For further details se...

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 16, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has made in cash the final maturity date payment of C$51.1 million (or approximately US$37.5 million) to Computershare Trust Company of Canada as trustee for holders of ...

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 6, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the closing of its bought-deal public offering of 3,389,900 units ( Units ) at a price of C$2.95 per Unit for aggregate gross proceeds to Medexus o...